Literature DB >> 12405908

Unusual sclerosing haemangiomas and sclerosing haemangioma-like lesions, and the value of TTF-1 in making the diagnosis.

A G Nicholson1, C Magkou, D Snead, H A Vohra, M N Sheppard, P Goldstraw, E Beddow, D M Hansell, W D Travis, B Corrin.   

Abstract

AIMS: Sclerosing haemangiomas typically comprise a mixture of four architectural patterns (papillary, sclerotic, solid and haemorrhagic) and two cell types, eosinophilic cuboidal epithelial lining cells and sheets of rounded cells with either eosinophilic or clear cytoplasm. In most instances, recognition of these architectural and cytological features provides sufficient evidence for diagnosis. This study presents and discusses the histogenesis of four cases where difficulties in diagnosis were encountered, and reports the value of the antibody TTF-1 in making the diagnosis. METHODS AND
RESULTS: Four cases with focal areas reminiscent of sclerosing haemangioma were reviewed and immunostained with an antibody panel including antibodies to TTF-1 and surfactant apoprotein A. Of these, one case was classified as sclerosing haemangioma combined with typical carcinoid, in which there was a mediastinal lymph node metastasis solely comprising the solid component of sclerosing haemangioma. The second was classified as an alveolar adenoma with sclerosing haemangioma-like areas. In the remaining two cases, diagnosis was confounded by presentation with predominantly cystic masses, the largest 70 mm in diameter. Immunohistochemically, TTF-1 was of greater value than surfactant apoprotein, in particular in identifying the solid component of sclerosing haemangioma when this was solely present.
CONCLUSION: Sclerosing haemangiomas should be considered in the differential diagnosis of cystic pulmonary masses. They may also present histologically as combined tumours and metastasize to mediastinal nodes, indicating an, albeit low, malignant potential. TTF-1 is a valuable antibody in identifying the presence of a sclerosing haemangioma when typical features are absent.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12405908     DOI: 10.1046/j.1365-2559.2002.01522.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  7 in total

1.  Coexistence of pulmonary sclerosing hemangioma and primary adenocarcinoma in the same nodule of lung.

Authors:  Wei Liu; Xiao-Ying Tian; Yang Li; Yong Zhao; Bin Li; Zhi Li
Journal:  Diagn Pathol       Date:  2011-05-20       Impact factor: 2.644

2.  Sclerosing pneumocytoma diagnosed by preoperative endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).

Authors:  Yuki Shiina; Yuichi Sakairi; Hironobu Wada; Hajime Tamura; Taiki Fujiwara; Takahiro Nakajima; Hidemi Suzuki; Masako Chiyo; Masayuki Ota; Satoshi Ota; Yukio Nakatani; Ichiro Yoshino
Journal:  Surg Case Rep       Date:  2018-03-09

3.  [Diagnosis and treatment for pulmonary sclerosing hemangioma].

Authors:  Shaohua Ma; Yu Sun; Changzheng Du; Zhen Liang; Hongchao Xiong; Keneng Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-08

4.  Clinical Characteristics of Malignant Pulmonary Sclerosing Pneumocytoma Based on a Study of 46 Cases Worldwide.

Authors:  Weidong Zhang; Dong Cui; Yaqian Liu; Kefeng Shi; Xia Gao; Rulin Qian
Journal:  Cancer Manag Res       Date:  2022-08-13       Impact factor: 3.602

5.  Sixteen cases of sclerosing hemangioma of the lung including unusual presentations.

Authors:  Gou Young Kim; Jhingook Kim; Yong Soo Choi; Ho Joong Kim; Geunghwan Ahn; Joungho Han
Journal:  J Korean Med Sci       Date:  2004-06       Impact factor: 2.153

6.  Multiple peripheral typical carcinoid tumors of the lung: associated with sclerosing hemangiomas.

Authors:  Young Kim; Yoo-Duk Choi; Beum Jin Kim; In-Jae Oh; Sang-Yun Song; Jong-Hee Nam; Chang-Soo Park
Journal:  Diagn Pathol       Date:  2013-06-17       Impact factor: 2.644

7.  Sclerosing hemangioma of the lung showing strong FDG avidity on PET scan: Case report and review of the current literature.

Authors:  Davide Patrini; Rajeev Shukla; David Lawrence; Elaine Borg; Martin Hayward; Nikolaos Panagiotopoulos
Journal:  Respir Med Case Rep       Date:  2015-12-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.